Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Harvard Business School
Dow
Johnson and Johnson
Baxter

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SIMBRINZA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for SIMBRINZA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01937299 Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Completed Alcon Research Phase 4 2013-10-01 The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy (TRAVATAN Z®).
NCT01937312 Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Completed Alcon Research Phase 4 2013-10-01 The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (PGA) monotherapy.
NCT01978600 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 4 2013-10-01 The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
NCT02167035 Comparison of Combigan BID Versus Simbrinza TID Recruiting Allergan Phase 4 2014-08-01 To compare Combigan BID vs Simbrinza TID in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
NCT02167035 Comparison of Combigan BID Versus Simbrinza TID Recruiting Cornerstone Health Care, PA Phase 4 2014-08-01 To compare Combigan BID vs Simbrinza TID in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
NCT02419508 SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) Recruiting Alcon Research Phase 4 2015-08-01 The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a PGA in patients with open-angle glaucoma or ocular hypertension.
NCT02730871 Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® Recruiting Alcon Research Phase 4 2016-06-01 The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in subjects with open-angle glaucoma or ocular hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SIMBRINZA

Condition Name

Condition Name for SIMBRINZA
Intervention Trials
Ocular Hypertension 6
Open-Angle Glaucoma 3
Glaucoma 2
Open Angle Glaucoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for SIMBRINZA
Intervention Trials
Ocular Hypertension 6
Glaucoma, Open-Angle 5
Glaucoma 4
Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for SIMBRINZA

Trials by Country

Trials by Country for SIMBRINZA
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for SIMBRINZA
Location Trials
Texas 3
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for SIMBRINZA

Clinical Trial Phase

Clinical Trial Phase for SIMBRINZA
Clinical Trial Phase Trials
Phase 4 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for SIMBRINZA
Clinical Trial Phase Trials
Completed 3
Recruiting 3
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for SIMBRINZA

Sponsor Name

Sponsor Name for SIMBRINZA
Sponsor Trials
Alcon Research 6
Cornerstone Health Care, PA 1
Allergan 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for SIMBRINZA
Sponsor Trials
Industry 7
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Dow
Colorcon
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.